10x Genomics Inc
For the period ended Mar 31, 2024. Filed Apr 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Apr 30, 2024
TXG$62.90-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | $141,006 | $134,285 |
| Cost of revenue | 48,092 | 35,895 |
| Gross profit | 92,914 | 98,390 |
| Operating expenses: | ||
| Research and development | 68,638 | 67,098 |
| Selling, general and administrative | 85,774 | 83,280 |
| Total operating expenses | 154,412 | 150,378 |
| Loss from operations | (61,498) | (51,988) |
| Other income (expense): | ||
| Interest income | 4,736 | 3,869 |
| Interest expense | (1) | (19) |
| Other expense, net | (1,040) | (1,516) |
| Total other income | 3,695 | 2,334 |
| Loss before provision for income taxes | (57,803) | (49,654) |
| Provision for income taxes | 2,146 | 1,093 |
| Net loss | $(59,949) | $(50,747) |
| Net loss per share, basic and diluted | $(0.50) | $(0.44) |
| Weighted-average shares of common stock used in computing net loss per share, basic and diluted | 119,394,180 | 115,619,869 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.